ASX 200
Checkout Our Recommendations for free - 7 day free trial Subscribe Now

Zelda Therapeutics Ltd - ZLD share price

Current Price: $ - -
Updated At: -

About

Zelira Therapeutics Ltd is an Australia-based biopharmaceutical company. The Company is focused on developing and clinically validating branded cannabinoid-based medicines for the treatment of a variety of medical conditions in its Rx business, including insomnia, autism and chronic non-cancer pain. The Company's lead product, Zenivol, is a cannabinoid-based medicine for treatment of chronic insomnia. The Company is engaged in human clinical trial programs focused on insomnia, autism and opioid reduction with activities in Australia and the United States. It is also focused on pre-clinical research examining the effects of cannabinoids in breast, brain and pancreatic cancer, as well as research and development of cannabinoids to treat diabetes-associated cognitive decline. Its SprinjeneCBD toothpaste product is a hemp-derived, oral care products containing cannabinoids and based on the patented technology of blackseed oil and zinc.

Company Profile

Market Cap: -
Enterprise Value: -
Shares Outstanding: -
Shares Float: -
P/E Ratio: -
PEG Ratio: -
Book Value: -
Revenue TTM: -
Div Yield: -
Earning Share: -
Dividend per Share: -
Profit Margin: -

Disclaimer: The above financial data is sourced from EODHD and is for informational purposes only. Veye does not guarantee the accuracy or completeness of this data. Investors should conduct their own research and consult with a financial advisor before making investment decisions.

Top Shareholders

Price Summary

Today's High -
Price High
Today's Low -
Price Low
52 Week High: -
Price High
52 Week Low: -
Price Low
Price High
Week's High: -
Price Low
Week's Low: -

Price Chart

Get Your FREE Report

Discover the Top ASX Stocks to Invest In 2026!

Expert Analysis of Top-Performing ASX Stocks

Market Insights and In-Depth Research

Buy, Sell, And Hold Recommendations

Almost There!

Enter your details to download the report

Success!

Preparing your download...